Capivasertib (Truqap)<\/strong>\u00a0blocks forms of the AKT protein, which is part of a signaling pathway inside cells (including cancer cells) that can help them grow. Other proteins in this pathway include the PI3K and PTEN proteins.<\/p>\n This drug can be used along with the hormone drug fulvestrant to treat advanced hormone receptor-positive, HER2-negative breast cancer, if the cancer cells have changes in any of the\u00a0PIK3CA<\/em>,\u00a0AKT1<\/em>, or\u00a0PTEN<\/em>\u00a0genes, and if the cancer has grown during or after treatment with hormone therapy. Your doctor will test your blood or tumor for these mutations before starting treatment with this drug.<\/p>\n If Capivasertib Tablets<\/strong> are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n TRUQAP (capivasertib) tablets, for oral use Initial U.S. Approval: 2023<\/strong><\/p>\n Note:<\/strong> Approval Date:<\/strong> 2023 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cCapivasertib Tablets<\/strong>\u201d based on the information you provide.<\/p>\nHow can 1 go about obtaining Capivasertib Tablets?<\/h3>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n","protected":false},"excerpt":{"rendered":"Capivasertib Tablets, for oral use Initial U.S. Approval: 2023<\/h2>\n
\n
\nProprietary Name:<\/strong> TRUQAP
\nActive Ingredient(s):<\/strong> capivasertib
\nFDA-approved use:<\/strong> To treat patients with HER2-negative breast cancer
\nDosage Form:<\/strong> Tablets
\nSummary of FDA-approved use on approval date:<\/strong> Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n